Eliem Therapeutics, Inc.
NASDAQ:ELYM
Overview | Financials
Company Name | Eliem Therapeutics, Inc. |
Symbol | ELYM |
Currency | USD |
Price | 5.11 |
Market Cap | 342,677,622 |
Dividend Yield | 0% |
52-week-range | 2.35 - 11.55 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Andrew Levin M.D., Ph.D. |
Website | https://www.eliemtx.com |
An error occurred while fetching data.
About Eliem Therapeutics, Inc.
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD